NO20063951L - Fremgangsmater og preparater til behansling av tumorer og metastatosk sykdom - Google Patents
Fremgangsmater og preparater til behansling av tumorer og metastatosk sykdomInfo
- Publication number
- NO20063951L NO20063951L NO20063951A NO20063951A NO20063951L NO 20063951 L NO20063951 L NO 20063951L NO 20063951 A NO20063951 A NO 20063951A NO 20063951 A NO20063951 A NO 20063951A NO 20063951 L NO20063951 L NO 20063951L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- preparations
- metastatic disease
- immunoglobulins
- treating tumors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 206010061289 metastatic neoplasm Diseases 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 4
- 102000018358 immunoglobulin Human genes 0.000 abstract 4
- 229940072221 immunoglobulins Drugs 0.000 abstract 3
- 206010027476 Metastases Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 abstract 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 229960005027 natalizumab Drugs 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 238000011277 treatment modality Methods 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 230000005751 tumor progression Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54194604P | 2004-02-06 | 2004-02-06 | |
| PCT/US2005/002860 WO2005076843A2 (fr) | 2004-02-06 | 2005-02-03 | Methodes et compositions de traitement de tumeurs et de maladie metastatique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20063951L true NO20063951L (no) | 2006-11-02 |
Family
ID=34860234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20063951A NO20063951L (no) | 2004-02-06 | 2006-09-05 | Fremgangsmater og preparater til behansling av tumorer og metastatosk sykdom |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20050255118A1 (fr) |
| EP (2) | EP1718310A4 (fr) |
| JP (1) | JP4996261B2 (fr) |
| KR (1) | KR20070009581A (fr) |
| CN (1) | CN1946407B (fr) |
| AR (1) | AR047534A1 (fr) |
| AU (1) | AU2005213324B2 (fr) |
| BR (1) | BRPI0507451A (fr) |
| CA (1) | CA2555365A1 (fr) |
| EA (1) | EA009873B1 (fr) |
| IL (1) | IL177201A0 (fr) |
| MX (1) | MXPA06008746A (fr) |
| NO (1) | NO20063951L (fr) |
| NZ (1) | NZ584288A (fr) |
| PE (1) | PE20060009A1 (fr) |
| TW (1) | TWI375563B (fr) |
| UY (1) | UY28741A1 (fr) |
| WO (1) | WO2005076843A2 (fr) |
| ZA (1) | ZA200606557B (fr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200506159B (en) | 2003-02-10 | 2006-10-25 | Elan Pharm Inc | Immunoglobulin formulation and method of preparation thereof |
| CN1956738B (zh) | 2004-01-09 | 2013-05-29 | 辉瑞大药厂 | MAdCAM抗体 |
| WO2007007152A2 (fr) * | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anticorps anti-madcam utilises pour le traitement de cancers metastatiques et du chlorome |
| CA2675291C (fr) * | 2007-01-11 | 2017-05-23 | Novo Nordisk A/S | Anticorps anti-kir, formulations et utilisations de celles-ci |
| CA2708262A1 (fr) * | 2007-12-07 | 2009-06-18 | Elan Pharmaceuticals, Inc. | Procedes et compositions pour traiter des tumeurs liquides |
| GB0800311D0 (en) * | 2008-01-09 | 2008-02-20 | Cytosystems Ltd | Apparatus and method for filtering biological material |
| US20110110940A1 (en) * | 2008-04-15 | 2011-05-12 | Oxigene, Inc. | Methods for Enhancing the Efficacy of Vascular Disrupting Agents |
| US20100158893A1 (en) * | 2008-12-19 | 2010-06-24 | Baxter International Inc. | Systems and methods for obtaining immunoglobulin from blood |
| SG175166A1 (en) * | 2009-04-17 | 2011-11-28 | Biogen Idec Inc | Compositions and methods to treat acute myelogenous leukemia |
| US20110158982A1 (en) * | 2009-10-05 | 2011-06-30 | The Regents Of The University Of Michigan | COMPOSITIONS AND METHODS FOR INHIBITING MAdCAM |
| WO2012048298A2 (fr) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Procédés et systèmes de culture et de récolte de cellules dans un système de bioréacteur à fibres creuses avec conditions de régulation |
| JP5847188B2 (ja) | 2010-10-25 | 2016-01-20 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | ｓＶＣＡＭおよび／またはｓＭＡｄＣＡＭレベルの差を関連付けることにより、アルファ−４インテグリン活性の差を決定するための方法 |
| WO2013013302A1 (fr) * | 2011-07-22 | 2013-01-31 | Pacylex Pharmaceuticals Inc. | Létalité synthétique et traitement anticancéreux |
| CA2863679A1 (fr) | 2011-08-17 | 2014-05-30 | Dennis Brown | Compositions et procedes pour ameliorer le benefice therapeutique de composes chimiques administres de maniere suboptimale, notamment des hexitols substitues tels que le dibromodulcitol |
| WO2014018913A2 (fr) * | 2012-07-27 | 2014-01-30 | University Of Connecticut | Compositions de santacruzamate a et analogues et procédés d'utilisation |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| RU2527154C1 (ru) * | 2013-03-27 | 2014-08-27 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ повышения биодоступности цисплатина в саркому -45, индуцированную в эксперименте |
| ES2728305T3 (es) * | 2013-04-29 | 2019-10-23 | Ogd2 Pharma | Uso como diana del gangliosido GD2 O-acetilado como una nueva estrategia terapéutica y de diagnóstico para cáncer de células madre cancerosas |
| WO2015073918A1 (fr) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expansion de cellules dans un bioréacteur |
| JP6855243B2 (ja) | 2014-01-24 | 2021-04-07 | エイアイ・セラピューティクス・インコーポレーテッド | 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物 |
| US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
| WO2016049421A1 (fr) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Alimentation programmée |
| KR20170098812A (ko) | 2014-11-07 | 2017-08-30 | 램 테라퓨틱스, 인코포레이티드 | 신장암의 치료에 사용하기 위한 아필리모드 |
| US20190209576A1 (en) | 2014-11-07 | 2019-07-11 | AI Therapeutics, Inc. | Apilimod for use in the treatment of colorectal cancer |
| WO2017004592A1 (fr) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Croissance cellulaire à l'aide de stimuli mécaniques |
| WO2017011907A1 (fr) | 2015-07-17 | 2017-01-26 | Pacylex Pharmaceuticals Inc. | Silençage épigénétique de nmt2 |
| US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| RU2650587C1 (ru) * | 2017-04-26 | 2018-04-16 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ модификации хронической болью злокачественного роста меланомы в16 у мышей |
| SG11202000298VA (en) | 2017-07-14 | 2020-02-27 | Pfizer | Antibodies to madcam |
| JP7520818B2 (ja) * | 2018-09-13 | 2024-07-23 | ンカルタ・インコーポレイテッド | 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法 |
| EP3773918A4 (fr) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | Récepteurs d'antigènes chimériques anti-cd19 et leurs utilisations en immunothérapie |
| GB2619893A (en) | 2021-03-23 | 2023-12-20 | Terumo Bct Inc | Cell capture and expansion |
| RU2765955C1 (ru) * | 2021-03-30 | 2022-02-07 | Елена Рудольфовна Милаева | Средство для ингибирования метастазирования в легких |
| RU2762730C1 (ru) * | 2021-03-30 | 2021-12-22 | Елена Рудольфовна Милаева | Средство для ингибирования метастазирования в легких |
| US12209689B2 (en) | 2022-02-28 | 2025-01-28 | Terumo Kabushiki Kaisha | Multiple-tube pinch valve assembly |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
| WO2024186193A1 (fr) * | 2023-03-08 | 2024-09-12 | 인제대학교 산학협력단 | Composition pour traitement anticancéreux systémique en radiothérapie localisée |
| AU2024282654A1 (en) | 2023-05-30 | 2025-12-04 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| CA2072249C (fr) | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Anticorps monoclonal humain liant specifiquement a la surface d'un antigene des membranes des cellules cancereuses |
| DK0678122T3 (da) * | 1993-01-12 | 2000-03-06 | Biogen Inc | Rekombinante anti-VLA4 antistofmolekyler |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| AU3559695A (en) | 1994-09-30 | 1996-04-26 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| WO1998037902A1 (fr) * | 1997-02-28 | 1998-09-03 | The Regents Of The University Of California | Inhibition de la liaison entre cellules au moyen d'ensembles lipidiques |
| MY153569A (en) * | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| DK1113810T3 (da) * | 1998-09-14 | 2009-04-06 | Univ Texas | Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding |
| DE60043308D1 (de) | 1999-12-16 | 2009-12-24 | Biogen Idec Inc | Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin |
| WO2002045653A2 (fr) * | 2000-12-08 | 2002-06-13 | Uab Research Foundation | Radiotherapie et chimiotherapie combinees avec l'administration d'un anticorps du recepteur du facteur de croissance |
| EP1401484A1 (fr) * | 2001-06-11 | 2004-03-31 | Transition Therapeutics Inc. | Polytherapies a base de vitamine b12 et d'interferon destinees au traitement des affections virales, proliferantes et inflammatoires |
| WO2003019136A2 (fr) * | 2001-08-06 | 2003-03-06 | The Regents Of The University Of California | Procedes d'inhibition d'angiogenese |
| PL215263B1 (pl) * | 2002-02-25 | 2013-11-29 | Elan Pharm Inc | Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku |
| EP1682179A4 (fr) * | 2003-11-05 | 2008-09-03 | Palingen Inc | Cytotoxicite augmentee de l'anticorps de liaison cdim contre les lymphocytes b |
| EP1701979A2 (fr) * | 2003-12-03 | 2006-09-20 | Xencor, Inc. | Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique |
-
2005
- 2005-02-03 NZ NZ584288A patent/NZ584288A/en not_active IP Right Cessation
- 2005-02-03 ZA ZA200606557A patent/ZA200606557B/en unknown
- 2005-02-03 EP EP05712339A patent/EP1718310A4/fr not_active Withdrawn
- 2005-02-03 AU AU2005213324A patent/AU2005213324B2/en not_active Ceased
- 2005-02-03 KR KR1020067018079A patent/KR20070009581A/ko not_active Abandoned
- 2005-02-03 CN CN2005800121486A patent/CN1946407B/zh not_active Expired - Fee Related
- 2005-02-03 JP JP2006552178A patent/JP4996261B2/ja not_active Expired - Fee Related
- 2005-02-03 BR BRPI0507451-7A patent/BRPI0507451A/pt not_active IP Right Cessation
- 2005-02-03 MX MXPA06008746A patent/MXPA06008746A/es active IP Right Grant
- 2005-02-03 EA EA200601433A patent/EA009873B1/ru not_active IP Right Cessation
- 2005-02-03 EP EP11005763A patent/EP2394652A3/fr not_active Withdrawn
- 2005-02-03 US US11/049,365 patent/US20050255118A1/en not_active Abandoned
- 2005-02-03 WO PCT/US2005/002860 patent/WO2005076843A2/fr not_active Ceased
- 2005-02-03 CA CA002555365A patent/CA2555365A1/fr not_active Abandoned
- 2005-02-04 PE PE2005000129A patent/PE20060009A1/es not_active Application Discontinuation
- 2005-02-04 UY UY28741A patent/UY28741A1/es unknown
- 2005-02-04 AR ARP050100431A patent/AR047534A1/es not_active Application Discontinuation
- 2005-02-05 TW TW094103833A patent/TWI375563B/zh not_active IP Right Cessation
-
2006
- 2006-08-01 IL IL177201A patent/IL177201A0/en unknown
- 2006-09-05 NO NO20063951A patent/NO20063951L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA009873B1 (ru) | 2008-04-28 |
| NZ584288A (en) | 2011-10-28 |
| WO2005076843A3 (fr) | 2006-01-26 |
| ZA200606557B (en) | 2008-02-27 |
| JP2007520557A (ja) | 2007-07-26 |
| AU2005213324B2 (en) | 2011-06-09 |
| CN1946407B (zh) | 2011-10-05 |
| PE20060009A1 (es) | 2006-02-11 |
| MXPA06008746A (es) | 2007-01-23 |
| EP2394652A3 (fr) | 2012-10-24 |
| BRPI0507451A (pt) | 2007-07-10 |
| UY28741A1 (es) | 2005-08-31 |
| TW200536556A (en) | 2005-11-16 |
| EP1718310A4 (fr) | 2009-05-06 |
| KR20070009581A (ko) | 2007-01-18 |
| AR047534A1 (es) | 2006-01-25 |
| AU2005213324A1 (en) | 2005-08-25 |
| CA2555365A1 (fr) | 2005-08-25 |
| EP1718310A2 (fr) | 2006-11-08 |
| US20050255118A1 (en) | 2005-11-17 |
| EA200601433A1 (ru) | 2007-02-27 |
| JP4996261B2 (ja) | 2012-08-08 |
| IL177201A0 (en) | 2006-12-10 |
| CN1946407A (zh) | 2007-04-11 |
| WO2005076843A2 (fr) | 2005-08-25 |
| TWI375563B (en) | 2012-11-01 |
| EP2394652A2 (fr) | 2011-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20063951L (no) | Fremgangsmater og preparater til behansling av tumorer og metastatosk sykdom | |
| MX2023005375A (es) | Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina. | |
| MX373790B (es) | Anticuerpos humanos a ligando de muerte programada 1 (pd-l1). | |
| DE602005016773D1 (de) | Antikrebs-antikörper mit reduzierter komplementfixierung | |
| ATE546158T1 (de) | Therapeutisches krebsmittel mit polymergebundenem antikörper | |
| DE602004027992D1 (de) | In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135 | |
| EA201992575A1 (ru) | Биомаркеры для терапии рака | |
| EA201391423A1 (ru) | Антитела к ассоциированному с почками антигену 1 и их антигенсвязывающие фрагменты | |
| ATE531388T1 (de) | Verwendung von anti-alpha5beta1-antikörpern zur hemmung der krebszellproliferation | |
| Robert et al. | Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients | |
| Yajima et al. | Anti-androgen therapy for the patients with recurrent and/or metastatic salivary duct carcinoma expressing androgen receptors: a retrospective study | |
| DE60030696D1 (de) | Spezifische antikörper für cyp1b1 | |
| O'Reilly et al. | A phase 2, open-label, multicenter study of durvalumab (MEDI4736)±tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS. | |
| Alsina et al. | Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer. | |
| Schadendorf et al. | Combi-D: Quality of Life (Qol) Impact of the Combination of Dabrafenib and Trametinib (D+ T) Versus Dabrafenib Monotherapy (D) in Patients with Braf V600E/K Unresectable or Metastatic Melanoma in a Phase III Trial | |
| Wang et al. | A combined local treatment with anti-PD-1 antibody and bone marrow derived dendritic cells after x-ray irradiation to subcutaneous melanoma in a murine model. | |
| DE60331834D1 (de) | VERWENDUNG EINES ANTIKÖRPERS ANTI-PTHrP(34-53) ALS ANTAGONIST VON PTHrP ZUR BEHANDLUNG VON NIERENZELLKARZINOMA | |
| Hellmann | 2.1 Preclinical Data–In Vitro and In Vivo | |
| Królicki et al. | Secondary glioblastoma multiforme–local alpha emitters targeted therapy with 213Bi-DOTA-substance P | |
| Ferhatoğlu | Clinicopathologic and prognostic features in appendiceal malignancies: Does tumor invasiveness matter? | |
| Yakovleva | Treatment for oral mucosal cancer | |
| Rusakov et al. | CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER | |
| Kang | Surgical Standardization in Extent of Lymph Node Dissection for Treating Intrahepatic Cholangiocelluar Carcinoma: Complete LN Dissection vs. LN Sampling: Complete LN Dissection vs. LN Sampling | |
| Kostyu et al. | DIFFERENTIATED SURGICAL TACTICS IN PATIENTS WITH LOCALLY ADVANCED BLADDER INVOLVEMENT PELVIC TUMORS | |
| Moiseenko et al. | ANATOMICAL LANDMARKS FOR ROBOTIC NERVE SPARING RADICAL PROSTATECTOMY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |